Dear Shareholders,

Here at VG Life Sciences (OTC-QB: VGLS), our mission is to save and improve lives through the development of transformative treatments for cancer, infectious diseases, and the chronic inflammation intrinsic to autoimmune diseases. We have made significant progress in a number of areas in the third quarter of 2015. We’d like to update you on our accomplishments.

Research

Hypertension

On July 28, 2015 Edward Inscho, Ph.D., from the University of Alabama at Birmingham, made an important presentation at Texas A & M University on using the VGLS patented drug VG1177 in research focused on the impact of inflammatory processes on renal microvascular function and hypertension.

Chronic inflammation is linked to hypertension, and kidney injury.

“Continued research focused on the immune system involvement may open novel therapeutic targets for inflammatory kidney disease and hypertension,” said Inscho.

VG1177 is a synthetic peptide that is an antagonist to the MHC Class II-associated invariant peptide (CLIP) for binding to the MHC peptide binding groove.

VGLS Chief Scientist M. Karen Newell-Rogers, Ph.D., an inventor of VG1177, postulates that self-peptide binding to MHC plays a key role in chronic inflammation and autoimmune diseases, including HIV/AIDS, hypertension, preeclampsia and traumatic brain injury.

Cancer

As reported previously, we have completed the Phase I clinical trial of our combination cancer therapy conducted at the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio. This trial involved patients with solid tumors and examined the safety and efficacy of hydroxychloroquine (HCQ) in combination with sorafenib (marketed as Nexavar®), co-developed by Bayer AG and Onyx Pharmaceuticals. VGLS holds Patent No. 9073985 covering the combination therapy used in this trial.

In Phase I, tumor reduction and stabilization was shown in a number of patients in the third and fourth cohorts, all of whom had higher doses of the combination therapy. The design of this clinical trial allowed us to conclude that these positive effects can be attributed to the combination therapy and not sorafenib alone.

The University of Texas is now starting a Phase II of this important clinical trial.

Auto Immune Diseases

Research has continued at our laboratory at Texas A & M University under the direction of VGLS Chief Scientist M. Karen Newell-Rogers, Ph.D. In collaboration with research scientists from leading institutions around the country, Dr. Newell-Rogers is actively pursuing applications of VG1177 in autoimmune diseases and chronic inflammatory conditions.

Additionally, our laboratory is testing three new peptides, VG1196, VG1197, and VG 1198, based on our chemist’s recommendations to pursue a version of VG1177 with enhanced stability, tolerability and solubility. These new peptides were received during the quarter from our pharmaceutical vendor Ambiopharm Inc.

Grants

Dr. Newell-Rogers was awarded $250,000 from the CURE Epilepsy Foundation to fund her research on the role of the immune system in post-traumatic epilepsy. She was also awarded $100,000 from an anonymous donor for further Lyme research. Both of these grants will test the efficacy of VG1177 in these diseases and its ability to reduce inflammation. .

Financial

The Company’s SEC attorney has recommended that VGLS increase the total number of authorized shares for compliance purposes and future planning. The total number of authorized shares will be increased to 300,000,000.

In Conclusion

The third quarter 2015 was busy and productive as VGLS continued to pursue its goals of moving its cancer therapy into Phase II clinical trials and expanded the research of its Targeted Peptide Technology (TPT) in combating autoimmune and infectious diseases.

In the fourth quarter of 2015 we will be focusing on completing a number of important studies so that we will be positioned to restart the animal safety studies of TPT in early 2016. Meanwhile, we will keep you updated with the latest news and exciting developments through company press releases.

Be well,

John P. Tynan
President & CEO
VG Life Sciences, Inc.

 

About VG Life Sciences Inc.

Santa Barbara, California-based VG Life Sciences, Inc., formerly known as Viral Genetics, is a biotechnology company focused on discovering and developing drug therapies for cancer, infectious disease, inflammatory disease, and autoimmune disorders. VGLS controls over 40 U.S. and international patents and pending patents protecting its exclusive biotech platform technologies.

For more information and upcoming events, visit www.vglifesciences.com, or find VG Life Sciences, Inc. on Facebook, Twitter, and LinkedIn.

Safe Harbor Statement and Forward-Looking Statements: This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences’ drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences Inc. or any other person that the objectives and plans of VG Life Sciences will be achieved.

Contact:

Terri Somers

Somers Media

Phone: (619) 991-2369

Email: tsomers@somersmedia.com

 

U.S. Patent Covers Group of Compounds Combined With Existing Treatments To Fight Drug-Resistant Cancers

SANTA BARBARA, Calif., June 22, 2015 – VG Life Sciences, Inc., (OTCQB: VGLS), a biotechnology company developing therapies for cancer, autoimmune and infectious diseases, announced that the U.S. Patent and Trademark Office (USPTO) will issue Patent No. 9073985 covering VGLS’ combination therapy for treating drug-resistant cancer by combining an autophagy inhibitor with a chemotherapy drug. In addition, the USPTO will extend the term of the patent an extra 684 days to account for the time taken to process the application.

“This patent strengthens and broadens VGLS’ intellectual property that has already been translated into promising results during Phase I clinical trials in which the combination therapies were shown to be safe and tolerable, while also showing tumor size reduction and stabilization in patients with metastatic cancers,” said John Tynan, VGLS Chief Executive.

Since cancer cells rapidly divide, they have very high energy demands. They employ unique mechanisms to meet these demands, mechanisms not found in healthy cells. VGLS’ technology targets those pathways that the cells may use to fuel themselves, inhibiting autophagy. Hydroxychloroquine, the inhibiting compound used in the combination therapy, disrupts the cancer cells’ metabolic strategies, weakens their repair functions, slows their growth and makes them more sensitive to the chemotherapy drugs.

VGLS has completed a Phase I clinical trial of the combination therapy at the Cancer Therapy & Research Center at the University of Texas Health Sciences Center at San Antonio. The trial involved patients with solid tumors and examined the safety and efficacy of Hydroxychloroquine (HCQ) in combination with sorafenib (marketed as Nexavar®) co-developed by Bayer AG and Onyx Pharmaceuticals. Primary investigator and medical oncologist Dr. Tyler Curiel, M.D., M.P.H., reported: “There are sufficient evaluable patients to conclude that this combination, maximum dose, and schedule are sufficiently safe for additional clinical testing. In addition, the study found tumor reduction and stabilization in a number of patients in the third and fourth cohorts who had higher dosing.”

About VG Life Sciences Inc.
Santa Barbara, California-based VG Life Sciences, Inc., formerly known as Viral Genetics, is a biotechnology company focused on discovering and developing drug therapies for cancer, infectious disease, and inflammatory, autoimmune disorders. VGLS controls over 40 U.S. and international patents and pending patents protecting its exclusive biotech platform technologies. For more information and upcoming events, visit www.vglifesciences.com or find VG Life Sciences, Inc. on Facebook, Twitter, and LinkedIn.

Safe Harbor Statement and Forward-Looking Statements
This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences’ drug compounds are approved by the U.S. FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences or any other person that the objectives and plans of VG Life Sciences will be achieved.

Visit www.VGlifesciences.com

Contact:
Allie Trabucco, Corporate Communications
VG Life Sciences, Inc.
Phone: (805) 879-9000
Email: atrabucco@vglifesciences.com

SOURCE VG Life Sciences Inc.

Dear Shareholders,

Here at VG Life Sciences, our mission is to save and improve lives through the development of transformative treatments for cancer, infectious diseases, and the chronic inflammation intrinsic to autoimmune diseases. We have made significant progress in a number of areas in the first half of 2015. We’d like to update you on our accomplishments.

Intellectual Property

Our intellectual property, a portfolio of over 40 U.S. and foreign patents and/or pending patent applications, is our primary asset. Earlier this year, that portfolio was strengthened with important new additions.

The U.S. Patent and Trademark Office (USPTO) issued a composition-of-matter patent covering methods for modulating immune system function through the targeting of CLIP (Class II-associated invariant chain peptide), which plays a key role in chronic inflammation and autoimmune diseases, including HIV/AIDS, hypertension, preeclampsia, and traumatic brain injury. U.S. Patent No. 8957031 covers the targeted peptide technology underlying VGLS’s VG1177, a synthetic peptide that has the ability to displace CLIP and block its harmful effects.

The USPTO also issued U.S. Patent No. 8906846, covering a method of treating inflammatory bowel disease (IBD). Over a million Americans have IBD and as of now are not medically curable.

The USPTO advised VGLS that it is issuing a use patent on the company’s hydroxychloroquine (HCQ)/sorafenib combination cancer treatment. VGLS is currently sponsoring clinical trials at the University of Texas using this combination treatment.

We also renegotiated an institutional licensing agreement with Scott & White Healthcare for the rights to certain tangential intellectual property. During those negotiations, our auditors required us to report that we withheld payment to Scott & White; shortly thereafter, a new agreement was executed, and we are current on all payments.

Research

As reported previously, we have completed our Phase 1 clinical trial conducted at the Cancer Therapy & Research Center at the University of Texas Health Science Center at San Antonio. This trial involved patients with solid tumors and examined the safety and efficacy of HCQ in combination with sorafenib (marketed as Nexavar®), co-developed by Bayer AG and Onyx Pharmaceuticals.

In Phase 1, tumor reduction and stabilization was shown in a number of patients in the third and fourth cohorts, all of whom had higher doses of the combination therapy. The design of this clinical trial allowed us to conclude that these positive effects can be attributed to the combination therapy and not sorafenib alone. FOR IMMEDIATE RELEASE 2 Visit www.VGlifesciences.com We are currently working with the University of Texas on the design and funding of the next phase of this important clinical trial.

Meanwhile, research has continued at our laboratory at Texas A & M University under the direction of VGLS Chief Scientist M. Karen Newell-Rogers, PhD. Collaborating with research scientists from leading institutions around the country, Dr. Newell-Rogers is actively pursuing applications of VG1177 in autoimmune diseases and chronically inflammatory conditions.

For the past 18 months, the Company has been conducting animal safety studies with our patented peptide VG1177, which is a significantly longer investigation than anticipated. In those studies, we have been unable to develop a proper dose response curve using direct and indirect methods for measuring peptide exposure in vivo.

Examples of the indirect methods we have used included a mouse epileptic seizure model (Theiler’s virus model) at the University of Utah and a rheumatoid arthritis rat model at Bolder BioPATH Laboratory in Colorado. Neither study generated the information necessary to develop a dose response curve.

Thus, we have implemented our chemist’s recommendations and modified VG1177 to increase its stability, while also improving its tolerability and solubility. These peptide modifications are not expected to alter VG1177’s biological activity.

After completing the modifications, we began conducting validation studies at our laboratory at Texas A & M University. We expect these studies to conclude in 2016. When they are completed, we intend to resume animal safety studies at ITV Laboratories in Canada. The animal safety studies are the next important step toward clinical trials.

Concurrently, we will continue using the original sequence of VG1177 in vivo and in vitro as a valuable tool to research the role of CLIP and invariant chain peptide in autoimmune and chronic inflammatory conditions.

Financial

In 2Q 2015, VGLS received a commitment of an additional $600,000 secured with convertible debentures and a further revolving line of credit from MedBridge Development LLC to meet our financial requirements.

For the remainder of 2015, we will complete the validating studies for our VG1177 modifications, restart the animal safety studies and expand our cancer clinical trial at the University of Texas. Meanwhile, we will keep you updated with the latest news and exciting developments through company press releases.

Be well,

John P. Tynan
President & CEO
VG Life Sciences, Inc.

About VG Life Sciences Inc.

Santa Barbara, California-based VG Life Sciences, Inc., formerly known as Viral Genetics, is a biotechnology company focused on discovering and developing drug therapies for cancer, infectious disease, inflammatory disease, and autoimmune disorders. VGLS controls over 40 U.S. and international patents and pending patents protecting its exclusive biotech platform technologies.

For more information and upcoming events, visit www. vglifesciences.com, or find VG Life Sciences, Inc. on Facebook, Twitter, and LinkedIn.

Safe Harbor Statement and Forward-Looking Statements: This news release may contain forward-looking statements that involve risks and uncertainties associated with financial projections, milestone timelines, clinical development, regulatory approvals and other risks described by VG Life Sciences from time to time in its periodic reports. None of VG Life Sciences’ drug compounds are approved by the US FDA or by any comparable regulatory agencies elsewhere in the world. Therefore, there can be no assurance that the forward-looking statements included in this release will prove to be accurate. In light of the significant uncertainties inherent in the forward-looking statements included herein, the forward-looking statements should not be regarded as a representation by VG Life Sciences Inc. or any other person that the objectives and plans of VG Life Sciences will be achieved.

 

 

 

Contact:
Media –
Terri Somers
Somers Media
terri@somersmedia.com
619-991-2369

SOURCE VG Life Sciences Inc.